Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,766 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,441 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,353)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02084563 | Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms | completed | Phase 2 | 455 | Hospital Israelita Albert EinsteinOTHER | 1 | Nov 8, 2016 | clinicaltrials |
| NCT01087151 | A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 12 | Nov 2, 2016 |
| NCT02949570 | Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study(ICT10) | unknown | Phase 2 | 54 | Hybrigenics CorporationINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT00025662 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | completed | Phase 2 | 23 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 28, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT00098371 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | terminated | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT02147873 | Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL | terminated | Phase 2 | 118 | TetraLogic PharmaceuticalsINDUSTRY | 4 | Oct 20, 2016 | clinicaltrials |
| NCT00691938 | LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 52 | Washington University School of MedicineOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT01772953 | Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT | completed | Phase 2 | 40 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Oct 12, 2016 | clinicaltrials |
| NCT00862719 | Sitagliptin Umbilical Cord Blood Transplant Study | completed | Phase 2 | 29 | Indiana UniversityOTHER | 1 | Oct 7, 2016 | clinicaltrials |
| NCT00147901 | Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) | completed | Phase 2 | 61 | German CLL Study GroupOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT00278265 | Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia | terminated | Phase 2 | 12 | German CLL Study GroupOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT02568241 | Interferon-α After DLI for the Prevention of Relapse(IDPR-HSCT) | unknown | Phase 1 / Phase 2 | 42 | Peking University People's HospitalOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT00276809 | Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | completed | Phase 2 | 30 | German CLL Study GroupOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT00281931 | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia | terminated | Phase 2 | 21 | German CLL Study GroupOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT02015208 | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 13 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT01113632 | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 77 | SCRI Development Innovations, LLCOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00800839 | Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01809847 | Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation | completed | Phase 2 | 20 | Technische Universität DresdenOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT00365768 | Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors | completed | Phase 2 | 56 | Columbia UniversityOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT02846584 | a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies | unknown | Phase 2 | 100 | Southwest Hospital, ChinaOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02888990 | Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia(EWALLPH01) | completed | Phase 2 | 71 | Versailles HospitalOTHER | 4 | Sep 5, 2016 | clinicaltrials |
| NCT01870596 | Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 1, 2016 | clinicaltrials |
| NCT00867672 | Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia(DECIDER) | completed | Phase 2 | 204 | University Hospital FreiburgOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01826214 | Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 30, 2016 | clinicaltrials |
| NCT00206726 | Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)(ECO-1) | completed | Phase 2 | 60 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2016 | clinicaltrials |
| NCT00771056 | Hydroxychloroquine in Untreated B-CLL Patients | terminated | Phase 2 | 23 | Northwell HealthOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT01051154 | Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia(DHA-ALL) | completed | Phase 2 | 72 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00814164 | Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT02115672 | Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Sheba Medical CenterOTHER_GOV | 1 | Aug 15, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT01960387 | Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia(UPCI 13-066) | terminated | Phase 2 | 2 | University of PittsburghOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT00072475 | Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes | completed | Phase 2 | 155 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02766868 | Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL | unknown | Phase 2 | 20 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02848183 | Optimal Treatment Strategy Based on for Pediatric AML | unknown | Phase 2 | 350 | Samsung Medical CenterOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT00133367 | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00079482 | Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 224 | CephalonINDUSTRY | 13 | Jul 21, 2016 | clinicaltrials |
| NCT00003248 | Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT00003675 | Topotecan in Treating Patients With Myelodysplastic Syndrome | completed | Phase 2 | 100 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT00006252 | Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 47 | Cancer and Leukemia Group BNETWORK | 1 | Jul 18, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT00006265 | Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 60 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00778375 | Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 122 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Nov 8, 2016source: clinicaltrials